L3VLUP
ProSign in

A · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • A
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterAJNJ
Q3 202018 holders, $7.1bn30 holders, $26.2bn
Q4 202017 holders, $7.8bn32 holders, $26.6bn
Q1 202120 holders, $7.2bn31 holders, $25.3bn
Q2 202119 holders, $8.5bn37 holders, $25.6bn
Q3 202122 holders, $8.5bn40 holders, $24.1bn
Q4 202122 holders, $8.5bn33 holders, $25.2bn
Q1 202224 holders, $6.8bn35 holders, $28.2bn
Q2 202224 holders, $6.5bn33 holders, $26.9bn
Q3 202219 holders, $4.5bn36 holders, $25.4bn
Q4 202224 holders, $6.2bn35 holders, $27.6bn
Q1 202327 holders, $6.0bn42 holders, $24.5bn
Q2 202321 holders, $4.7bn38 holders, $25.0bn
Q3 202321 holders, $4.0bn37 holders, $18.9bn
Q4 202316 holders, $4.9bn31 holders, $19.0bn
Q1 202412 holders, $5.3bn32 holders, $19.7bn
Q2 202413 holders, $4.2bn35 holders, $20.4bn
Q3 202416 holders, $4.9bn28 holders, $22.3bn
Q4 202417 holders, $4.3bn37 holders, $20.4bn
Q1 202517 holders, $3.8bn32 holders, $20.5bn
Q2 202513 holders, $3.8bn31 holders, $18.4bn
Q3 202515 holders, $3.9bn32 holders, $23.7bn
Q4 202517 holders, $4.6bn29 holders, $27.8bn
Q1 202621 holders, $4.0bn34 holders, $35.6bn
Q2 202615 holders, $5.1bn33 holders, $39.1bn
A

Agilent Technologies Inc

Holders
17
Reported value
$4.3bn
Buyers
14
Sellers
4

Breadth +10 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 39 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only A (2)

ExodusPoint Capital Management LP, Two Sigma Investments LP

Only JNJ (22)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Janus Henderson Group Ltd, Markel Group Inc, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →